Blogs about: Mtor
Featured Blog
Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I
Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765 to show demonstrate ‘robust pharmacodymanics’… more →
Kinase News
Is a Fountain of Youth Within Reach?
drnyssa wrote 4 months ago: Imagine we if could slow our aging and prevent onset of age-related diseases. The science behind th … more →
mTOR, oligodendrocyte differentiation and demyelinating disorders
annalsofneurology wrote 6 months ago: Although studies have identified multiple factors involved in oligodendrocyte fate commitment, littl … more →
Keryx: Another beneficiary of the ASCO-effect
Michael Becker wrote 6 months ago: By Michael D. Becker In my prior article, I highlighted the “ASCO-effect,” which relates to the fact … more →
TORKinib
kinasepro wrote 8 months ago: aka: PP242 is gettin that academic preclinical press @ PLoS Biology, and ScienceDaily. Nothing says … more →
Melanoma Study at CORT Testing Targeted Therapeutic Agents
— 1 comment
bmirtsching wrote 11 months ago: Metastatic melanoma remains one of the most difficult to treat malignancies for oncologists. This c … more →
Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765 … more →
Of "autophagy" and prostate cancer
Sitemaster wrote 1 year ago: It is beginning to seem likely that over the next year or two we may start to hear more about a biol … more →
ARIAD begin Phase II study of Deforolimus in Prostate Cancer
crimsoncanary wrote 1 year ago: ARIAD/Merck have initiated a Phase II clinical trial to evaluate the safety and efficacy of mTOR inh … more →
ARIAD to present data on Deforolimus and AP24534 at EORTC-NCI-AACR
crimsoncanary wrote 1 year ago: ARIAD will present new data on mTOR inhibitor deforolimus, and multikinase inhibitor AP24534 at the … more →
RAD001/Sandostatin combo shows efficacy in pancreatic cancer
crimsoncanary wrote 1 year ago: Data presented at the European of Medical Oncology (ESMO) show that combining RAD001 with Sandostati … more →
Kidney cancer patients treated with RAD001 reach 5 months without tumor growth
crimsoncanary wrote 1 year ago: Data presented at the European of Medical Oncology (ESMO) show that kidney patients treated with RAD … more →
Novartis granted priority review for everolimus in advanced kidney cancer
crimsoncanary wrote 1 year ago: Novartis have announced that RAD001 (everolimus) has been granted priority review by the US FDA for … more →
Sirolimus found to cause veno-occlusive disease (VOD)
crimsoncanary wrote 1 year ago: Sirolimus has been found to cause veno-occlusive disease (VOD) after TBI-based transplantation, and … more →
Novartis PI3K/mTOR inhibitor NVP-BEZ235 inhibit VEGF induced Angionesis/Cell proliferation
crimsoncanary wrote 1 year ago: Novartis’ dual PI3K/mTOR inhibitor NVP-BEZ235 has been found to inhibit VEGF-induced cell prol … more →
AstraZeneca initiate Phase I/II trial of mTOR inhibitor AZD8055
crimsoncanary wrote 1 year ago: AstraZeneca have initiated a Phase I/II trial of mTOR inhibitor AZD8055 in Advance Solid Tumors, Lym … more →
NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer
crimsoncanary wrote 1 year ago: The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary r … more →
ARIAD initiate Phase II trial of deforolimus in Endometrial Cancer
crimsoncanary wrote 1 year ago: ARIAD Pharmaceuticals have announced the initiation of a phase II clinical trial of mTOR inhibitor d … more →
ARIAD commence Phase II trial of oral deforolimus in breast cancer
crimsoncanary wrote 1 year ago: ARIAD have announced the initiation of a Phase II clinical trial of mTOR inhibitor Deforolimus in Pa … more →
Everolimus can improve progression-free survival in advanced renal cell carcinoma
crimsoncanary wrote 1 year ago: Data published in the Lancet shows that treatment with mTOR inhibitor everolimus can significantly i … more →
